Adjunct Faculty

Barry Berkowitz, Ph.D.

University of California, San Francisco. Adjunct Professor of Pharmacology. Founder, Chairman, and Chief Executive Officer, Strong Pharma, LLC. Strong has founded several companies including: Myco/ChemGenics, Fibrogen and New Chemical Entities (sold to Albany Molecular). Strong is currently organizing a new company which utilizes a compelling and novel business model to increase the efficiency of and accelerate drug development.

Michael Byrne, Ph.D.

Cornell University, Ithaca, NY. Adjunct Associate Professor of Pharmacology. Director of Biochemistry, ALTANA Research Institute, ALTANA Pharma, Waltham, MA.
Research Interests: drug discovery and development, technology development, target identification and validation using RNA interference, research management, patent liaison.

Dennis W. Choi, M.D., Ph.D.

Harvard University/Harvard Medical School, Boston, MA. Adjunct Professor of Pharmacology. Director, Emory University Neuroscience Center, and Vice President of Academic Affairs, Woodruff Health Sciences Center, Emory University, Atlanta. GA. Dr. Choi oversees the development of four key areas: neuroscience education, behavioral neuroscience and cognition, brain therapeutics, and molecular and translational imaging research.

Andrew Dorner, Ph.D.

State University of New York, Stony Brook. Adjunct Professor of Pharmacology. Senior Director, Molecular Medicine, Millennium Pharmaceuticals, Cambridge MA.
Research Interests: include the development of nucleic acid therapeutics, biomarker applications and translational medicine.

Ruth E. Gimeno, Ph.D.

Massachusetts Institute of Technology. Adjunct Associate Professor of Pharmacology. Principal Research Scientist II/Principal Research Scientist III, Cardiovascular and Metabolic Diseases, Pfizer Global Biotherapeutics Technologies, Pfizer, Inc., Cambridge, MA.
Research Interests: Development of novel therapeutics for obesity and type 2 diabetes. Areas of interest include appetite regulation,insulin resistance and energy expenditure, and pancreatic beta cell function.

Marion Kasaian, Ph.D.

Case Western Reserve University. Adjunct Associate Professor of Pharmacology. Principal Research Scientist IV, Inflammation and Immunology, Pfizer Global Biotherapeutic Technologies, Pfizer, Inc., Cambridge, MA.
Research interests: Cellular and innate immune mechanisms contributing to inflammatory diseases, with a focus on asthma.

Zhijian Lu, Ph.D.

Boston University. Adjunct Associate Professor of Pharmacology. Director, Extramural Partnered Research, Asia, Pfizer Global Biotherapeutic Technologies, Pfizer, Inc., Cambridge, MA.
Research Interests: My current research focus is in the areas of biotherapeutics discovery. We use modern technologies such as genomics and proteomics to identify targets suitable for biotherapeutic intervention, and try to understand the biological functions of these targets in order to set up assays and animal models for testing drug candidates.

John C. McKew, Ph.D.

University of California, Davis. Adjunct Associate Professor of Pharmacology. National Institutes of Health, Bethesda, MD.
Research Interests:Research interests include medicinal chemistry, synthetic methodology and tool compounds to probe biology. This research has been directed against targets in Inflammation, Cardiovascular, Metabolic Disease, and Muscle Biology.

Steven M. Paul, M.D., B.A.

Tulane University. Adjunct Professor of Pharmacology. Executive Vice President, Science and Technology; President, Lilly Research Laboratories, Eli Lilly and Company.
Research Interests: Mechanisms of action of centrally acting pharmacologic agents, neurotransmitters, and hormones.

Steven Projan, Ph.D.

Adjunct Professor of Pharmacology, Vice President, Global Head of Infectious Disease, Novartis Institutes for Biomedical Research, Cambridge, MA

Carl E. Rosow, M.D., Ph.D., a.B.

Oberlin College; M.D. Boston University School of Medicine, Ph.D. Boston University. Adjunct Associate Professor of Pharmacology, School of Medicine; Professor of Anaethesia, Harvard Medical School.
Research Interests: the pharmacokinetics and pharmacodynamics of opioids and sedative hypnotic drugs.

Robert G. Schaub, Ph.D.

Washington State University. Adjunct Professor of Pharmacology. Vice President Preclinical Discovery, Archemix Corp; Cambridge, MA. Current research interests are directed to two areas. One is on the role of platelets and leukocytes in the pathophysiology of peripheral circulatory disease and thrombosis. The other is the identification of new treatments for coagulation deficiencies like hemophilia A, hemophilia B and other rare bleeding disorders.

Cara M. M. Williams, Ph.D.

University of Liverpool.

Adjunct Associate Professor of Pharmacology. Director of Tissue Inflammation, Biotherapeutics Research, Pfizer, Inc. in Cambridge, Massachusetts.

Clive Wood, Ph.D.

Imperial College, London. Adjunct Professor of Pharmacology. Senior Vice President and Head, Global Biologics, Global Drug Discovery, Bayer Schering Pharma AG in Wuppertal, Germany;

Discovery and preclinical development of innovative therapeutics for inflammation and oncology. Current areas of focus include antibody and small protein-based inhibitors of proteases.

Bryan K. Yamamoto Ph.D.

Syracuse University. Adjunct Professor of Pharmacology. Professor and Chairman, Neurosciences Department, University of Toledo.
Research Interests: A primary research focus is in neuropharmacology and is related to the neurotoxicity of the amphetamines, particularly methamphetamine and MDMA (Ecstasy)